Delving into the Latest Updates on Cetrorelix with Synapse

The purpose of this study is to assess the efficacy and safety of follitropin alfa/lutropin alfa in Japanese participants with Luteinizing hormone (LH) and Follicle stimulating hormone (FSH) deficiency undergoing Assisted reproductive technology (ART).
The study duration is approximately 5.5 months for nonpregnant participants and 13 months for participants with confirmed pregnancy in Part A.

Start Date31 Jan 2026

Sponsor / Collaborator

Merck Healthcare KGaA

[+1]

IRCT20240806062668N1

/ RecruitingPhase 3IIT

Comparison of clomiphene citrate and Cetrotide in IVF (In Vitro Fertilization)cycles to prevent LH surge and pregnancy results.

Start Date10 Aug 2024

Sponsor / Collaborator-

NCT06378268

/ RecruitingNot ApplicableIIT

Effectiveness of Progestin-Primed Ovarian Stimulation Versus GnRH Antagonist Protocol for Ovarian Stimulation in IVF: a Randomized Clinical Trial

This non-inferiority randomized controlled trial will be conducted at My Duc Hospital, Ho Chi Minh City, Vietnam.
This study compares the effectiveness of Progestin-Primed Ovarian stimulation versus GnRH protocol for ovarian stimulation in IVF treatment. Participants will be randomly assigned in a 1:1 ratio to receive Progestins or GnRH antagonists.

Start Date24 Apr 2024

Sponsor / Collaborator-

100 Clinical Results associated with Cetrorelix

Login to view more data

100 Translational Medicine associated with Cetrorelix

Login to view more data

100 Patents (Medical) associated with Cetrorelix

Login to view more data

731

Literatures (Medical) associated with Cetrorelix

31 Dec 2026·Human Fertility

Oocyte cryo-preservation for fertility preservation: a comparative study of efficacy and cost-effectiveness between progestin-primed and antagonist ovarian stimulation protocol

Article

Author: Sherlock, K. ; Kastora, S. ; Alabi, C. ; Vaughan, E. ; Yasmin, E. ; Lavery, S. ; Balachandren, N. ; Atik, Y. ; Davies, M. C.

Suppression of an LH surge is fundamental to successful oocyte retrieval after controlled ovarian stimulation. This study evaluates the efficacy and cost-effectiveness of progestin-primed ovarian stimulation (PPOS) using oral medroxyprogesterone acetate in fertility preservation cycles. The design is a retrospective single-centre study (January 2022-August 2023) comparing two ovarian stimulation protocols: PPOS and the gonadotrophin-releasing hormone antagonist (GnRHant) protocols. Cycles began at any time of the menstrual cycle. The primary outcome was the number of metaphase II oocytes retrieved. Secondary outcomes included total oocytes retrieved, maturity ratio, stimulation duration, incidence of premature LH rise/ovulation events, and the cost of medication used to prevent ovulation. The study included 125 fertility preservation cycles: 54 in the PPOS group and 71 in the GnRHant group. Median body mass index, antral follicle count, and anti-Mullerian hormone levels were comparable between the two groups. The median age was younger in the PPOS group; 28 years vs. 32 years, p = 0.03. Mature oocyte retrieval was similar; mean 9.33 [SD 5.87] vs. 8.97 [SD 5.44], p = 0.73. No premature LH rises occurred in either group. Secondary outcomes showed no significant differences, except for the cost of medication used to prevent ovulation. The PPOS protocol was considerably more cost-effective, by achieving a 98.06% cost reduction (medroxyprogesterone acetate, mean £4.38 [SD, £1.10] vs cetrorelix acetate £226.2 [SD £64.36], p= <0.0001. PPOS is a practical, cost-effective strategy for fertility preservation. Its appeal lies in its patient-centric focus, with a less invasive injection-based administration, while maintaining comparable effectiveness and significant cost reduction compared with the GnRH antagonist ovarian stimulation protocol.

01 Feb 2026·THERIOGENOLOGY

Effect of a GnRH antagonist on the fate of the dominant ovarian follicle and the emergence of the next follicular wave in alpacas

Article

Author: Singh, Jaswant ; Shakeel, Muhammad A ; Munteanu, Miruna ; Adams, Gregg P

The objectives of the study were to determine the effects of dose (double vs single) of a GnRH antagonist (Cetrorelix) and follicular status (known status vs random status) on ovarian follicular wave synchrony. In Experiment 1, we tested the hypotheses that treatment of alpacas with two doses of Cetrorelix, will cause 1) regression of the dominant ovarian follicle during both its mid-growing and mid-static phases, and 2) emergence of a new follicular wave at a consistent time after treatment. Ovarian ultrasonography was performed daily and alpacas (n = 7 per group; Day 0 = wave emergence) were given 1.5 mg Cetrorelix acetate im twice at an interval of 24 h starting on Day 5 (mid-growing dominant follicle, D5), Day 10 (mid-static phase, D10) or remained untreated (Control). The mean day of onset of dominant follicle regression was earlier in the D5 group than in the D10 and Control groups (Day 8.7 ± 0.89, 12.9 ± 0.34, 13.6 ± 0.90, respectively; P < 0.001). The largest diameter of dominant follicle was smallest in the D5 group (P = 0.003). The inter-wave interval was shortest in the D5 group (12.7 ± 0.36 days), intermediate in Control (14.6 ± 0.81) and longest in the D10 group (17.7 ± 0.52; P < 0.001). The interval from treatment to wave emergence was similar between D5 and D10 groups (7.7 ± 0.36 days vs 7.7 ± 0.52 days; P > 0.99). In Experiment 2, we tested the hypothesis that a single dose of 1.5 mg Cetrorelix will induce emergence of a new follicular wave synchronously among a group of alpacas on random days of the follicular wave. A new wave emerged 5.3 ± 0.70 days later (n = 15) and was more synchronous (lower variance) than in the pre-treatment control period (Barlett's test p = 0.049, Levene's test p = 0.025). In conclusion, treatment with a single or double dose of 1.5 mg Cetrorelix caused the demise of dominant follicle leading to synchronous emergence of the next follicular wave 5 days (single dose) or 8 days (two doses) later. Results document the potential utility of Cetrorelix in breeding management protocols that enable pre-scheduled, synchronous insemination.

01 Feb 2026·AQUATIC TOXICOLOGY

Crosstalk with the cholinergic pathway may be responsible for chlorpyrifos-induced reproductive toxicity in fish

Article

Author: Li, Shuying ; Guan, Yanru ; Cui, Haisong ; Xu, Yanmei ; Zhou, Shengli ; Wang, Aoxue ; Wen, Zexin ; Jiang, Yuyao ; Jin, Miqi ; Yan, Yujia ; Gui, Wenjun

Chlorpyrifos (CPF), a commonly applied organophosphate insecticide, is known to disrupt the endocrine systems of aquatic species. However, further research is required to elucidate the molecular mechanisms involved in the reproductive toxicity of fish. In the present study, zebrafish were exposed to environmentally relevant concentrations of CPF (1, 10, and 50 μg/L) for a 21-day period. Within the concentration range at which chlorpyrifos significantly inhibits the activity of acetylcholinesterase in zebrafish, there is a significant decrease in reproductive capacity of 31.65 %. The RNA-seq analysis has revealed that processes such as transporter activity, reproduction, and reproductive function are affected. Elevated FSH and LH levels in CPF-exposed females were observed at concentrations of 10 μg/L and 50 μg/L. Furthermore, the CPF treatment resulted in the upregulation of esr2b, hsd3b1, fshr, gnrh2, vtg1, and vtg2, while cyp19a1a was found to be downregulated. Co-exposure to cetrorelix acetate, a potent GnRH receptor antagonist, has been demonstrated to normalize gene expression and restore E₂ levels. These results suggest that CPF-induced reproductive toxicity involves crosstalk between cholinergic signaling and the HPG axis. These findings underscore the complex toxicity and ecological risks associated with CPF.

12

News (Medical) associated with Cetrorelix

25 Feb 2026

·www.biospace.com

Trump Calls on Congress To Codify Most Favored Nation Drug Pricing in SOTU

White House , screengrab In his State of the Union address on Tuesday evening, President Donald Trump urged Republican leaders to pass legislation cementing his new drug pricing initiatives as he touted his efforts to lower healthcare costs for Americans. President Donald Trump called on Congress to codify his Most Favored Nation drug pricing initiative into law, as he delivered the State of the Union address at the Capitol in Washington, D.C. on Tuesday evening. He also touted his efforts to lower drug prices and the success of deals with pharma companies that were signed over the fall. “Under my just enacted Most Favored Nation agreements, Americans who have for decades paid by far the highest prices of any nation anywhere in the world for prescription drugs will now pay the lowest price anywhere in the world for drugs,” Trump said, according to a transcript of the event. “I took prescription drugs, a very big part of healthcare, from the highest price in the entire world to the lowest. That’s a big achievement.” The White House launched the TrumpRx platform in February , offering select drugs from major pharma companies on a direct-to-consumer basis. Analysts have been skeptical of the program’s ability to lower out-of-pocket costs for patients, as many of the drugs offered were heading for a patent cliff and would be lowered anyway. Other experts also questioned the impact of the program, which would likely only serve uninsured patients or those with high-deductible plans. Most patients would have access to steeper discounts via their regular insurance plans. Pfizer was the first company to sign an MFN deal last year, soon to be followed by the likes of AstraZeneca, Amgen, Bristol Myers Squibb and more. The CEOs of Eli Lilly and Novo Nordisk attended a joint announcement at the White House in November to offer their GLP-1 products, including initial doses of upcoming oral weight loss medicines, for $150. Many of the companies reached the agreements in exchange for exemption from tariffs. Drug pricing How Effective Will TrumpRx and Other Direct-to-Consumer Drug Pricing Initiatives Be? With pricing pressures climbing, Pfizer, Eli Lilly and other major drugmakers are looking to sell their products directly to patients. Analysts are skeptical that these efforts, including those announced to much fanfare from the White House, will result in meaningful reductions in drug spending. November 12, 2025 · 11 min read · Tristan Manalac Read More Trump said the TrumpRx platform has lowered drug prices “300, 400, 500, 600 percent and more.” The president specifically pointed to medicines for in vitro fertilization, which are not typically covered by insurance plans. In October, Merck KGaA’s U.S. subsidiary EMD Serono announced an agreement with the U.S. government to broaden access to its fertility medications, including Gonal-F, Ovidrel and Cetrotide. In his address, Trump called out one patient in attendance who was able to access IVF medications for less, Catherine Rayner. Rayner was the first person to utilize the TrumpRx platform, according to the president. “One drug has been costing Catherine $4,000 to purchase. But a few weeks ago, she logged on to the website and got that same drug that cost costs $4,000, got it for under $500, a reduction of much more actually than $3,500,” Trump said. “Catherine, we are all praying for you and you’re going to be a great mom.” With Rayner as an example, Trump urged his Republican leaders in Congress to codify Most Favored Nation drug pricing. “I’m not sure it matters because it’s going to be very hard for somebody that comes along after me to say, let’s raise drug prices by 700 or 800 percent. But John and Mike, if you don’t mind, codify it anyway,” he said, referring to Senate Majority Leader John Thune and House Speaker Mike Johnson. Trump already urged Congress to address MFN in a January announcement of “The Great Healthcare Plan,” which seeks to take the drug pricing fight to insurers. Drug pricing Despite MFN Deals, Drug Pricing Will Dog Pharma Into 2026 Only a handful of the top pharmas have signed Most Favored Nation drug pricing deals with the White House, while smaller biotechs continue to hang in limbo. January 6, 2026 · 5 min read · Annalee Armstrong Read More

17 Oct 2025

·www.fiercepharma.com

Merck KGaA's EMD Serono strikes MFN deal in Trump's fertility treatment pricing push

Merck KGaA’s U.S. arm EMD Serono is the latest to join President Donald Trump's most-favored nation pricing push, following AstraZeneca and Pfizer. Merck KGaA’s U.S. arm EMD Serono is joining President Donald Trump’s most-favored nation drug pricing push with an agreement to sell its fertility therapies at a sharp discount through the government’s TrumpRx direct-to-consumer purchasing platform.The company will offer its full in vitro fertilization (IVF) drug portfolio, including Gonal-f, Cetrotide and Ovidrel, to eligible patients, with an 84% discount for the use of all three therapies in a typical IVF regimen when TrumpRx goes live in 2026. Citing the Centers for Medicare & Medicaid Services, the White House said the price cuts could save patients up to $2,200 per IVF cycle. Fertility medications make up almost 20% of the total cost of treatment, which can total between $15,000 and $30,000 for one round, according to GoodRx. The new public-private partnership with EMD Serono complies with Trump’s February executive order on expanding access to IVF, the company said in a Thursday press release. The White House said EMD Serono will offer other drugs at deep discounts when sold directly to patients and guarantee MFN prices on new medicines, while the company separately said it reached a Commerce Department agreement to exclude its products from Section 232 tariffs in return for U.S. manufacturing and research investments.EMD Serono already has a strong U.S. presence and looks “forward to growing our footprint here even further with future fertility manufacturing,” CEO of Merck KGaA, Darmstadt, Germany’s Belén Garijo said in the company's release.“We are committed to working with the U.S. administration to add value over the long term, ensuring that our patients and customers continue to have access to and benefit from the innovations within our portfolio,” Garijo added.According to the White House, the agreement marks the “first time in history” that EMD Serono is investing in U.S. manufacturing. The company has long operated in the U.S. and moved its headquarters to Boston in 2023.EMD Serono’s Gonal-f was first approved in the late 90s as one of the first recombinant human products used to treat infertility. Since then, the Merck KgaA unit has built out its fertility franchise to include other complementary products and devices, with the next addition now coming to the U.S. sooner, with a potential FDA Commissioner’s National Priority Voucher (CNPV).CNPV for IVF The company’s Pergoveris, a combination of recombinant human follicle-stimulating hormone (r-hFSH) and recombinant human luteinizing hormone (r-hLH) that’s designed to “mimic reproductive physiology,” will soon be filed for FDA review under its CNPV program. The program applies to products that align with U.S. national health priorities and reduces the FDA’s review timeline from about 10 to 12 months to one to two months. FDA Commissioner Marty Makary, M.D., launched the CNPV program in June and announced the first nine recipients on Oct. 16. Other than EMD Serono’s Pergoveris for infertility, investigational products from Regeneron, Sanofi and others made the cut to treat diseases ranging from diabetes, deafness and blindness, to name a few.Pergoveris is already widely available outside the U.S. If it wins U.S. approval, the White House said patients could benefit further from lower prices thanks to increased competition in the fertility drug market.Along with the administration’s deal with EMD Serono, it announced new guidance for employers to offer standalone benefit packages for IVF and infertility. One in 8 U.S. couples struggles with fertility, according to EMD Serono, which describes itself as “the leader in fertility therapeutics.”EMD Serono joins AstraZeneca and Pfizer in complying with Trump’s MFN pricing demands, which look to tie U.S. prices to lower costs overseas. Much of the deal implores companies to sell their drugs directly to patients, which many have already embraced. Others, like Bristol Myers Squibb, will roll out their drugs in the U.K. at higher U.S.-linked prices.

Drug Approval

17 Oct 2025

·firstwordpharma.com

TrumpRx welcomes Merck KgaA, one of nine to receive new priority voucher

Merck KGaA is the latest drugmaker to slash some of its products' US list prices in exchange for an exemption from President Donald Trump's 100% pharmaceutical tariff — and one of the first to receive a new kind of speedy review voucher from the FDA.The third pharma to reach a most-favoured nation (MFN) drug pricing deal with the Trump administration, Merck — through its US-based healthcare business unit, EMD Serono — will make its in vitro fertilization (IVF) therapies available through a direct-to-consumer (DTC) platform that patients with prescriptions will be able to reach via the government-run TrumpRx website, due to launch in January. The company said on Thursday that if all three of its IVF offerings — Gonal-f (follitropin alfa injection), Ovidrel (choriogonadotropin alfa injection) and Cetrotide (cetrorelix acetate for injection) — are used in a single IVF protocol, patients will pay 84% less than the total list price. While AstraZeneca's and Pfizer's respective MFN deals earned them each a three-year grace period from tariffs, Merck said in a release that its pharmaceutical products and ingredients will be excluded from tariffs, without a time limit, "provided EMD Serono invests in future biopharmaceutical manufacturing and research in the United States."The German drugmaker "look[s] forward to growing our footprint here even further with future fertility manufacturing," said Belén Garijo, CEO and chair of Merck, in a company release.A new kind of priority reviewAnd more fertility options for US patients are on the way. In conjunction with the MFN deal, Merck also announced that it's part of the inaugural cohort of companies to receive one of the FDA's new Commissioner’s National Priority Vouchers (CNPVs). The pharma plans to use its voucher to accelerate review of Pergoveris, an IVF therapy that combines recombinant human follicle stimulating hormone (r-hFSH) and recombinant human luteinizing hormone (r-hLH) in a single injection pen. The product has been approved in Europe since 2017. With the CNPV, Merck is promised a regulatory decision on Pergoveris within one to two months after filing the application, along with "enhanced" communication with FDA staff during the review process. The US regulator had said in June it planned to start handing out CNPVs to drugmakers "addressing our most important US national priorities," either by attempting to solve a health crisis, upping domestic manufacturing or developing an innovative treatment. In July, FDA Commissioner Marty Makary suggested that companies that promise to "equalise" the cost of their drugs between the US and other countries could also qualify for a CNPV.In addition to Merck's Pergoveris, the FDA on Thursday revealed eight other products that have earned a CNPV, including Regeneron's hearing loss gene therapy DB-OTO; the company had announced plans to file for FDA approval of the one-time treatment just days earlier.Another CNPV went to Sanofi's anti-CD38 antibody teplizumab to treat type 1 diabetes. Initially approved by the FDA in 2022 to delay the onset of stage 3 type 1 diabetes in adults and children aged 8 years and older who have stage 2 disease, the French pharma gained teplizumab through its $2.9-billion takeout of Provention Bio in 2023.Revolution Medicines has snagged a voucher for pancreatic cancer treatment daraxonrasib (RMC-6236); it started a registrational trial of the pan-RAS inhibitor in October 2024. Disc Medicines will get a fast review for bitopertin, having just submitted an application on Sept. 30 for the oral GlyT1 inhibitor to treat erythropoietic protoporphyria, including X-linked protoporphyria.FDA approved for neurotrophic keratitis in 2018, Dompé Farmaceutici's cenegermin received a voucher for blindness. Other recipients include Achieve Life Sciences' nicotine vaping addiction treatment cytisinicline, as well as domestically manufactured versions of ketamine and Augmentin XR, an antibiotic.

Drug ApprovalPriority Review

100 Deals associated with Cetrorelix

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D01685	Cetrorelix	H01CC02	DB00050

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Infertility, Female	Australia	Merck Healthcare Pty Ltd.	19 Dec 2000
Suppression of ovulation	Australia	Merck Healthcare Pty Ltd.	19 Dec 2000
Obstetric Labor, Premature	United States	EMD Serono, Inc.	11 Aug 2000
Primary Ovarian Insufficiency	European Union	Merck Europe BV	12 Apr 1999
Primary Ovarian Insufficiency	Iceland	Merck Europe BV	12 Apr 1999
Primary Ovarian Insufficiency	Liechtenstein	Merck Europe BV	12 Apr 1999
Primary Ovarian Insufficiency	Norway	Merck Europe BV	12 Apr 1999

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Polycystic Ovary Syndrome	Phase 3	France	-	12 Mar 2008
Endometriosis	Phase 2	Australia	Solvay Pharmaceuticals, Inc.	01 Nov 2005
Endometriosis	Phase 2	Belgium	Solvay Pharmaceuticals, Inc.	01 Nov 2005
Endometriosis	Phase 2	Bulgaria	Solvay Pharmaceuticals, Inc.	01 Nov 2005
Endometriosis	Phase 2	Germany	Solvay Pharmaceuticals, Inc.	01 Nov 2005
Endometriosis	Phase 2	Romania	Solvay Pharmaceuticals, Inc.	01 Nov 2005
Endometriosis	Phase 2	Russia	Solvay Pharmaceuticals, Inc.	01 Nov 2005
Endometriosis	Phase 2	South Africa	Solvay Pharmaceuticals, Inc.	01 Nov 2005
Endometriosis	Phase 2	Ukraine	Solvay Pharmaceuticals, Inc.	01 Nov 2005

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02478775 (CTgov)	Not Applicable	Infertility \| Obesity	99	Cetrorelix (Experimental: Frequent Blood Sampling, Cetrorelix: Normal Weight)	iaylzbeqib(ojnrnkviel) = xmjdzlswjn dzbdbxekxb (mhfbgdvtub, 73.7) View more	-	07 Apr 2022
				Cetrorelix (Experimental: Frequent Blood Sampling, Cetrorelix: Obese)	iaylzbeqib(ojnrnkviel) = wpegpasinl dzbdbxekxb (mhfbgdvtub, 37.9) View more
NCT04537078 (CTgov)	Phase 3	Infertility, Female	90	Gonadotropin+Decapeptyl+Cyclo-Progynova+progesterone+Duphaston (the Progestin Primed Double Stimulation Group)	yslfkqfkat(jidolgdxdo) = bewynetrzi pxqenltwms (rvielbrlfp, sgemepaagz - rfdkoyvhdc) View more	-	17 Feb 2022
				Chorionic Gonadotropin+Cetrotide Injectable Product+Decapeptyl+Cyclo-Progynova+progesterone (the Flexible GnRh Antagonist)	doivxuyqnd(lfuxgyjoel) = licckdpdnx bepdxftuxi (ltywmotxzy, ngkabvpkel - ckabhiindn) View more
NCT02823080 (CTgov)	Phase 2/3	Ovarian Hyperstimulation Syndrome \| Infertility	48	Cetrorelix (Cetrotide)	brwxjtgjzo(hbscgjjolq) = uzulimbaav xbkfyuvawi (bfhibmptde, 940) View more	-	31 Jan 2017
				daysCetrorelix Acetate (no Cetrotide)	brwxjtgjzo(hbscgjjolq) = ypywcchnrx xbkfyuvawi (bfhibmptde, 792) View more
NCT01457703 (CTgov)	Not Applicable	Obesity	62	Recombinant LH+Cetrorelix+Letrozole+Gonadorelin-GnRH (BMI ≥30 kg/m2)	wfuhjndccy(xsomntawbl) = ucrsmnskqg btkdnlyvnb (zrwsoafpuk, zkjgfcfktv - qdnblxivuz) View more	-	25 Mar 2015
				Recombinant LH+Cetrorelix+Letrozole+Gonadorelin-GnRH (BMI 18-25 kg/m2)	wfuhjndccy(xsomntawbl) = yalskfzikz btkdnlyvnb (zrwsoafpuk, hxfzlzmmcf - mgzxromici) View more
NCT00667758 (AGRA, Pubmed \| PLoS One)	Phase 2	Rheumatoid Arthritis	99	Cetrorelix	iwbcsyfeul(eqmadirkhi) = cakbbaqtrn iomrdrcugg (etykdgrtkp )	-	01 Jan 2015
NCT01225835 (PREDICT, CTgov)	Phase 4	Infertility	124	Menotrophin+Choriongonadotropin+Cetrorelix+progesterone (Menotrophin)	ixanqyswds(lhvguuerpe) = hkatrjsliq tbmbtplcwz (bftrkxkdxx, 0.34) View more	-	11 Feb 2014
				Choriongonadotropin+Cetrorelix+progesterone+Follitrophin alpha (Follitrophin Alpha)	ixanqyswds(lhvguuerpe) = jpljtyycah tbmbtplcwz (bftrkxkdxx, 0.41) View more
NCT00866034 (CTgov)	Phase 4	Infertility	617	Cetrotide (Early Start CD2)	wjuvgcelvu = zclbdxbxhi wuunortzsf (gdxhatrpnq, csipzjdfoj - zgfqduwnyt) View more	-	17 Dec 2013
				Cetrotide (Late Start CD6)	wjuvgcelvu = wlzwpyangg wuunortzsf (gdxhatrpnq, qwhucflisl - gvwmuelani) View more
NCT01185704 (ATTAC-PCO, CTgov)	Phase 3	Polycystic Ovary Syndrome	136	Cetrorelix acetate+Recombinant Human Choriogonadotropin (r-hCG)+Recombinant human follicle stimulating hormone (r-hFSH) (Day 1 Protocol)	iwaryobbld(lyzcvdyfdg) = zgzgzhrusf bkkyxktcqm (fztnwnbnvc, 862.62) View more	-	03 Jul 2013
				Cetrorelix acetate+Recombinant Human Choriogonadotropin (r-hCG)+Recombinant human follicle stimulating hormone (r-hFSH) (Day 7 Protocol)	iwaryobbld(lyzcvdyfdg) = larhmghsyv bkkyxktcqm (fztnwnbnvc, 835.49) View more
NCT00867659 (CTgov)	Not Applicable	Ovarian Hyperstimulation Syndrome \| Ovarian Stimulations	20	Cetrotide acetate	sbqggavejz(pycxcodvpo) = aetqrzmhkh mzstnqzoxp (qnpmlrvtiv, hygdovfywk - ttyqvmkmse) View more	-	27 Mar 2013
NCT00667758 (EULAR2012)	Phase 2	Rheumatoid Arthritis TNF-α	99	Cetrorelix	deqazvxrah(diiszoeciw) = demrjlqist jggyxafyor (psuuhvtyvu ) View more	-	06 Jun 2012
				Placebo	deqazvxrah(diiszoeciw) = ftgjgvunmn jggyxafyor (psuuhvtyvu ) View more

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data